Inhibition of α4β1 Integrin Activity by Small Tellurium Compounds Regulates PD-L1 Expression and Enhances Antitumor Effects

Overview

Journal Int J Biol Sci

Specialty Biology

Date 2024 Sep 9

PMID 39247817

Authors

Abigael Chaouat

Yona Kalechman

Ophir Hay

Julia E Manoim

Tal Lantner

Eitan Niderberg

Hagit Hauschner

Dvora Kenigsbuch Sredni

Tal Cohen

Agata Schlesinger

Ronia Nadler

Mira Barda-Saad

Elad Noy

Michael Albeck

Dan L Longo

Benjamin Sredni

Affiliations

Soon will be listed here.

Abstract

Various cancer treatment approaches that inhibit the activity of the programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) axis, a key player in tumor immune evasion, have been developed. We show that the immunomodulatory small tellurium complexes AS101 (ammonium trichloro(dioxoethylene-o,o')tellurate) and SAS (octa-O-bis(R,R)-tartarate ditellurane) suppress PD-L1 expression in a variety of human and mouse malignant cells via the modulation of α4β1 very late antigen- (VLA-4) integrin activity. Consequently, the expression of pAkt and its downstream effector pNFκB are inhibited. Additionally, SAS promotes the death of mouse malignant cells by activated syngeneic splenocytes or CD8 T cells, preventing the development of chemoresistance in malignant cells. Moreover, AS101 and SAS may increase, at least in part, chemosensitivity through inhibition of the VLA-4/IL-10/PD-L1 pathway. Additionally, AS101 or SAS treatment of B16/F10 melanoma-bearing mice decreased tumor cell PD-L1 expression, leading to increased CD8 T-cell infiltration into the tumors and tumor shrinkage. Combination treatment with an αPD-1 antibody and either tellurium compound significantly increased the antitumor efficacy of immunotherapy. Overall, VLA-4 integrin signaling is critical for tumor immune evasion and is a potential target for cancer treatment. Finally, AS101 or SAS, biologically active tellurium compounds, can effectively enhance the therapeutic efficacy of αPD-1-based cancer immunotherapy.

References

Sredni B . Immunomodulating tellurium compounds as anti-cancer agents. Semin Cancer Biol. 2011; 22(1):60-9. DOI: 10.1016/j.semcancer.2011.12.003. View

Ott P, Hu-Lieskovan S, Chmielowski B, Govindan R, Naing A, Bhardwaj N . A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer. Cell. 2020; 183(2):347-362.e24. DOI: 10.1016/j.cell.2020.08.053. View

Okun E, Arumugam T, Tang S, Gleichmann M, Albeck M, Sredni B . The organotellurium compound ammonium trichloro(dioxoethylene-0,0') tellurate enhances neuronal survival and improves functional outcome in an ischemic stroke model in mice. J Neurochem. 2007; 102(4):1232-41. DOI: 10.1111/j.1471-4159.2007.04615.x. View

Halpert G, Eitan T, Voronov E, Apte R, Rath-Wolfson L, Albeck M . Multifunctional activity of a small tellurium redox immunomodulator compound, AS101, on dextran sodium sulfate-induced murine colitis. J Biol Chem. 2014; 289(24):17215-27. PMC: 4059162. DOI: 10.1074/jbc.M113.536664. View

Elong Edimo W, Schurmans S, Roger P, Erneux C . SHIP2 signaling in normal and pathological situations: Its impact on cell proliferation. Adv Biol Regul. 2013; 54:142-51. DOI: 10.1016/j.jbior.2013.09.002. View

Danoch H, Kalechman Y, Albeck M, Longo D, Sredni B . Sensitizing B- and T- cell Lymphoma Cells to Paclitaxel/Abraxane-Induced Death by AS101 via Inhibition of the VLA-4-IL10-Survivin Axis. Mol Cancer Res. 2014; 13(3):411-22. DOI: 10.1158/1541-7786.MCR-14-0459. View

Grandage V, Gale R, Linch D, Khwaja A . PI3-kinase/Akt is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NF-kappaB, Mapkinase and p53 pathways. Leukemia. 2005; 19(4):586-94. DOI: 10.1038/sj.leu.2403653. View

Vanneman M, Dranoff G . Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer. 2012; 12(4):237-51. PMC: 3967236. DOI: 10.1038/nrc3237. View

Errico A . Immunotherapy: PD-1-PD-L1 axis: efficient checkpoint blockade against cancer. Nat Rev Clin Oncol. 2014; 12(2):63. DOI: 10.1038/nrclinonc.2014.221. View

10.

Sredni B, Tichler T, Shani A, Catane R, Kaufman B, STRASSMANN G . Predominance of TH1 response in tumor-bearing mice and cancer patients treated with AS101. J Natl Cancer Inst. 1996; 88(18):1276-84. DOI: 10.1093/jnci/88.18.1276. View

11.

Cai H, Yan L, Liu N, Xu M, Cai H . IFI16 promotes cervical cancer progression by upregulating PD-L1 in immunomicroenvironment through STING-TBK1-NF-kB pathway. Biomed Pharmacother. 2020; 123:109790. DOI: 10.1016/j.biopha.2019.109790. View

12.

Chen J, Zhang X, Proud C . Dissecting the signaling pathways that mediate cancer in PTEN and LKB1 double-knockout mice. Sci Signal. 2015; 8(392):pe1. DOI: 10.1126/scisignal.aac8321. View

13.

Lee S, Yang H, Kim W, Lee Y, Lee W, Kong S . STING activation normalizes the intraperitoneal vascular-immune microenvironment and suppresses peritoneal carcinomatosis of colon cancer. J Immunother Cancer. 2021; 9(6). PMC: 8215239. DOI: 10.1136/jitc-2020-002195. View

14.

Gowrishankar K, Gunatilake D, Gallagher S, Tiffen J, Rizos H, Hersey P . Inducible but not constitutive expression of PD-L1 in human melanoma cells is dependent on activation of NF-κB. PLoS One. 2015; 10(4):e0123410. PMC: 4386825. DOI: 10.1371/journal.pone.0123410. View

15.

Lin K, Cheng J, Yang T, Li Y, Zhu B . EGFR-TKI down-regulates PD-L1 in EGFR mutant NSCLC through inhibiting NF-κB. Biochem Biophys Res Commun. 2015; 463(1-2):95-101. DOI: 10.1016/j.bbrc.2015.05.030. View

16.

Antonangeli F, Natalini A, Garassino M, Sica A, Santoni A, Di Rosa F . Regulation of PD-L1 Expression by NF-κB in Cancer. Front Immunol. 2020; 11:584626. PMC: 7724774. DOI: 10.3389/fimmu.2020.584626. View

17.

Vivanco I, Sawyers C . The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer. 2002; 2(7):489-501. DOI: 10.1038/nrc839. View

18.

Lacour M, Hiltbrunner S, Lee S, Soltermann A, Rushing E, Soldini D . Adjuvant Chemotherapy Increases Programmed Death-Ligand 1 (PD-L1) Expression in Non-small Cell Lung Cancer Recurrence. Clin Lung Cancer. 2019; 20(5):391-396. DOI: 10.1016/j.cllc.2019.05.013. View

19.

Jiang X, Zhou J, Giobbie-Hurder A, Wargo J, Hodi F . The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition. Clin Cancer Res. 2012; 19(3):598-609. DOI: 10.1158/1078-0432.CCR-12-2731. View

20.

Bouillez A, Rajabi H, Jin C, Samur M, Tagde A, Alam M . MUC1-C integrates PD-L1 induction with repression of immune effectors in non-small-cell lung cancer. Oncogene. 2017; 36(28):4037-4046. PMC: 5509481. DOI: 10.1038/onc.2017.47. View